Pediatric hematologist-oncologist explores the complex relationship between cancer treatment’s toxicities and reduced nutritional intake.
A treatment-resistant paraspinal mass in a 24-year-old patient was affecting his ability to walk. Its location made local control nearly impossible. A novel agent and committed care team were able to change course and shrink the tumor with radium-223, an alpha emitting therapeutic.
The small molecule ONC201 has shown promise as an effective, well-tolerated drug in the treatment of neuroendocrine tumors (NETs), report the authors of a Cleveland Clinic-led study.
When a 4-year-old patient was diagnosed with a rare type of Ewing sarcoma, her team of pediatric and surgical oncologists came together with a plan that deviated slightly from the traditional treatment paradigm. This approach, her physicians say, allowed them to salvage significant anatomy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new study led by Cleveland Clinic researchers suggests that the small molecule ONC201 has promise as a less toxic treatment for pheohromocytomas/paragangliomas, and possibly other rare neuroendocrine tumors as well.
Results of a Phase 2 trial offer much-needed guidance to clinicians treating a rare and aggressive form of sarcoma. Dr. Peter Anderson explains.
With greater precision made possible through image guidance, radiotherapy combined with new chemotherapeutics means radiation will be desirable instead of feared in childhood cancer therapy.
This noted pediatric osteosarcoma expert shares his proudest discovery and a few reflections on patient care as he settles in at Cleveland Clinic Children’s.